Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

A panel of federal health experts recommended expanded vaccine options for several diseases, including RSV, meningitis, and chikungunya.

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

A new global study led by GlaxoSmithKline has found that a single dose of the RSV vaccine Arexvy (RSVPreF3 OA) offers strong ...

At its first meeting under the new administration, the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted on recommendations for several ...

Canada is just emerging from another winter wave of multiple infectious diseases only for the population to be confronted ...

CDC panel expands Pfizer and GSK RSV vaccine use to high-risk adults 50–59, building on earlier recommendations for older ...

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...

The CDC’s Advisory Committee on Immunization Practices voted April 16 to expand use of respiratory syncytial virus vaccines among high-risk adults. The updated recommendation calls for a single ...

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...

GSK GSK and Pfizer PFE announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on ...